Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study

Myer, Emily N. B.; Petrikovets, Andrey; Slocum, P.; Lee, Toy Gee; Carter-Brooks, Charelle M.; Noor, Nabila; Carlos, Daniela; Wu, Enboa; Eck, Kathryn Van; Fashokun, Tola; Yurteri-Kaplan, Ladin A.; Chen, Grace

doi:10.1016/j.ajog.2018.04.005

Cited by 21 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies have focused on surgical site infection in patients undergoing SNM . BMI, immunosuppression , and having a postoperative hematoma or a deep pocket >3 cm have been reported as independent risk factors for explantation due to infection. Gender was not identified as a risk factor for explantation, but very few studies included long‐term surgical infections , and of the ones that did, the rate for men was low.…”

Section: Discussionmentioning

confidence: 99%

Is Sacral Nerve Modulation a Good Option for Fecal Incontinence in Men?

Brochard

Mège

Bridoux

et al. 2019

Neuromodulation: Technology at the Neural Interface

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Is Sacral Nerve Modulation a Good Option for Fecal Incontinence in Men?

Brochard

Mège

Bridoux

et al. 2019

Neuromodulation: Technology at the Neural Interface

View full text Add to dashboard Cite

“…Risk factors have been proposed, such as comorbidities, longer duration of test phase (stage 1 ), need for surgical reinterventions and pocket hematoma. So far, there is no clear evidence whether a history of neurological disease would be a risk factor for infection ( 29 ).…”

Section: Methodsmentioning

confidence: 99%

Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction?

2020

View full text Add to dashboard Cite

Purpose: To review current literature regarding sacral neuromodulation (SNM) for neurogenic lower urinary tract dysfunction (NLUTD) focused on indications, barriers and latest technological developments. Material and Methods: A PubMed database search was performed in April 2020, focusing on SNM and various neuro-urological conditions. Results: SNM has been increasingly indicated for lower urinary tract dysfunction (LUTD) in neuro-urological patients. Most studies are cases series with several methodological limitations and limited follow-up, lacking standardized definition for SNM clinical success. Most series focused on neurogenic overactive bladder in spinal cord injured (incomplete lesions) and multiple sclerosis patients. Barriers for applying this therapy in neurogenic LUTD were mainly related to magnetic resonance imaging incompatibility, size of the implantable pulse generator (IPG), and battery depletion. Newer technological advances have been made to address these limitations and will be widely available in the near future. Conclusions: SNM seems a promising therapy for neurogenic LUTD in carefully selected patients with incomplete lesions. Further studies are still needed to define which subgroups of neurological patients benefit the most from this minimally invasive technique.

show abstract

“…In a multicenter retrospective case-control assessment of risk factors for explantation of the SNM device due to infection, researchers reported on an almost 2-3% incidence of infection and identified that hematoma formation and IPG pocket depth of greater than 3 cm were independently associated with development of infection, while implant infection was the leading cause of device explantation at 1 year follow-up in another large trial [68,73,76]. The most common pathogen reported on cultures obtained from these explants was the skin flora resident S. aureus.…”

Section: Implant Infectionmentioning

confidence: 99%

“…The most common pathogen reported on cultures obtained from these explants was the skin flora resident S. aureus. Infection is probable both early in the postoperative period within 30 days of implantation, or later beyond 30 days and sometimes up to 10 months post-implantation [73,76].…”

Section: Implant Infectionmentioning

confidence: 99%

Neuromodulation in Urology: Current Trends and Future Applications

Yaiesh¹,

Al‐Terki²,

Al-Shaiji³

2020

Neurostimulation and Neuromodulation in Contemporary Therapeutic Practice

View full text Add to dashboard Cite

Urological applications of neuromodulation and neurostimulation are among the most evolving fields for these technologies. First approved for management of refractory urge incontinence, different modalities of neuromodulation and stimulation have been tested, applied and verified for a vast spectrum of voiding and pelvic floor dysfunction disorders. The modalities of delivering this treatment have also evolved in the last three decades, with a focus on sacral neuromodulation. The experimental and established "off-label" applications of neuromodulation have also encompassed chronic pelvic pain disorders, including chronic prostatitis and bladder pain syndrome, among others. In this chapter, we discuss all the hypothesized theories suggested on how this technology provides therapeutic potential for a number of chronic and debilitating urological conditions, the modes of delivery be it anterior, sacral, and posterior tibial to name a few, and the evolving and future applications.

show abstract

Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study

Cited by 21 publications

References 17 publications

Is Sacral Nerve Modulation a Good Option for Fecal Incontinence in Men?

Is Sacral Nerve Modulation a Good Option for Fecal Incontinence in Men?

Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction?

Neuromodulation in Urology: Current Trends and Future Applications

Contact Info

Product

Resources

About